Viatris (VTRS), a global healthcare company announced that it and Kindeva Drug Delivery L.P. have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca’s (AZN) Symbicort patent, U.S. Patent No. 10,166,247, is invalid. The district court determined that the patent is invalid on two separate grounds – lack of written description and lack of enablement. Viatris President Rajiv Malik said: "We are extremely pleased with the court’s decision as it clears away yet another of AstraZeneca’s invalid patents, which have only served to block generic versions and delay access to this important product for American patients. This affirms Viatris’ continuing efforts to break down barriers to patient access for important medicines. We already have FDA approval for our generic Symbicort product, and we look forward to the opportunity to bring our more affordable product to market."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VTRS:
- Top Viatris (NASDAQ:VTRS) Executive Charged With Insider Trading
- Viatris upgraded to Neutral from Sell at UBS
- Regeneron Eylea IPR losses ‘mostly anticipated,’ says RBC Capital
- USPTO board says Mylan has shown claims of Regeneron patent ‘unpatentable’
- Biotech Alert: Searches spiking for these stocks today